The present invention relates to compounds of Formula (I)
and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
作者:Thomas Jozak、Dirk Zabel、Anett Schubert、Yu Sun、Werner R. Thiel
DOI:10.1002/ejic.201000802
日期:2010.11
RuCl2(PPh3)3, RuHCl(CO)(PPh3)3 and RuH2(CO)(PPh3)3 to form ruthenium complexes bearing protic N–H groups in close proximity to the catalytically active ruthenium centre. In the case of the hydridoruthenium complex RuHCl(CO)(PPh3)3 the resulting complexes also contain abasic hydrido ligand. The combination of acidic and basic hydrogen species in one molecule and the arising two-site reactivity was thoroughly
Compounds and methods of synthesizing oxysterols are provided. The compounds and methods provided allow the oxysterol to be safely produced at a high yield. The compounds and methods provided can produce the oxysterol in a stereoselective manner.
METHODS FOR THE SEPARATION AND DETECTION OF AN OXYSTEROL
申请人:Warsaw Orthopedic, Inc.
公开号:US20170273990A1
公开(公告)日:2017-09-28
Assay methods for determining purity of a sample of a sterol are provided. These methods include providing an HPLC eluent including a sterol, other compounds related to the sterol and a mobile volatile phase; generating an aerosol of liquid droplets from the HPLC eluent; drying the liquid droplets to obtain residue particles of the sterol; contacting the residue particles of the sterol with an ion stream which applies a size-dependent electrical charge to each of the residue particles to generate an electrical signal and measuring the electrical signal to determine the purity of the sterol in the sample. The sterol can be OXY133 or OXY133 monohydrate.
POLYMORPHIC FORMS OF AN OXYSTEROL AND METHODS OF MAKING THEM
申请人:Warsaw Orthopedic, Inc.
公开号:US20180162900A1
公开(公告)日:2018-06-14
Compositions and methods for preparing OXY133 polymorphs Form C to Form I are provided. The methods include subjecting a slurry of OXY133 to conditions sufficient to convert OXY133 to the OXY133 polymorph Form C, polymorph Form D, polymorph Form E, polymorph Form F, polymorph Form G, polymorph Form H, polymorph Form I or a mixture thereof. A polymorph of OXY133 is also provided and that polymorph can be polymorph Form C, polymorph Form D, polymorph Form E, polymorph Form F, polymorph Form G, polymorph Form H, polymorph Form I or a mixture thereof. Pharmaceutical compositions including OXY133 polymorphs are also provided.